Volumen: 17 # Number : 2
Publication Date : Mayo - Agosto Year: 2013
Authors: Verón DA.
Abstract: Nowadays, most of children and adolescents with Hodgkin lymphoma can be cured. This scene challenged
us to look beyond 5 years to know the true impact of our treatment ant obligates us to reduce the costs of survival. We are now building a future where therapy could be refined and will allow us to cure more children with less toxicity. Ideas that are being discussed include better definition of risk groups, better definition of response with the use of PET/TC scanning, avoidance of high doses and multiple cycles of drugs with unacceptable toxicity profiles and use of even more refined radiotherapy. Involved nodal therapy is one of such innovation. Otherwise, the standard management of relapsed or refractory Hodgkin lymphoma should include the autologous stem cell transplantation in patient who are chemotherapy sensitive. Prognostic factors
for relapsed/refractory disease should be used as part of risk adapted therapy. Allogeneic transplantation
should be offered in the context of clinical
trials. An expanding list of novel agents will offer new alternatives in the management of this particular disease.
Key words: pediatric Hodgkin lymphoma, relapsed/refractory Hodgkin lymphoma, salvage chemotherapy,
transplantation, new drugs
Pages : 159-168
|
